1
|
Shao Y, Molestak E, Su W, Stankevič M, Tchórzewski M. Sordarin - the antifungal antibiotic with a unique modus operandi. Br J Pharmacol 2021; 179:1125-1145. [PMID: 34767248 DOI: 10.1111/bph.15724] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 09/13/2021] [Accepted: 10/18/2021] [Indexed: 12/01/2022] Open
Abstract
Fungal infections cause serious problems in many aspects of human life, in particular infections in immunocompromised patients represent serious problems. Current antifungal antibiotics target various metabolic pathways, predominantly the cell wall or cellular membrane. Numerous compounds are available to combat fungal infections, but their efficacy is far from being satisfactory and some of them display high toxicity. The emerging resistance represents a serious issue as well; hence, there is a considerable need for new anti-fungal compounds with lower toxicity and higher effectiveness. One of the unique antifungal antibiotics is sordarin, the only known compound that acts on the fungal translational machinery per se. Sordarin inhibits protein synthesis at the elongation step of the translational cycle, acting on eukaryotic translation elongation factor 2. In this review, we intend to deliver a robust scientific platform promoting the development of antifungal compounds, in particular focusing on the molecular action of sordarin.
Collapse
Affiliation(s)
- Yutian Shao
- Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, PR China.,Department of Molecular Biology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Lublin, Poland
| | - Eliza Molestak
- Department of Molecular Biology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Lublin, Poland
| | - Weike Su
- Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, PR China.,National Engineering Research Center for Process Development of Active Pharmaceutical Ingredients, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, PR China.,Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, PR China
| | - Marek Stankevič
- Department of Organic Chemistry, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie Sklodowska University, Lublin, Poland
| | - Marek Tchórzewski
- Department of Molecular Biology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Lublin, Poland
| |
Collapse
|
2
|
Standaert-Vitse A, Aliouat-Denis CM, Martinez A, Khalife S, Pottier M, Gantois N, Dei-Cas E, Aliouat EM. SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs. PLoS One 2015; 10:e0130358. [PMID: 26103633 PMCID: PMC4477875 DOI: 10.1371/journal.pone.0130358] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 05/18/2015] [Indexed: 11/18/2022] Open
Abstract
While Pneumocystis pneumonia (PcP) still impacts the AIDS patients, it has a growing importance in immunosuppressed HIV-negative patients. To determine the anti-Pneumocystis therapeutic efficacy of new compounds, animal and in vitro models have been developed. Indeed, well-designed mouse or rat experimental models of pneumocystosis can be used to describe the in vivo anti-Pneumocystis activity of new drugs. In vitro models, which enable the screening of a large panel of new molecules, have been developed using axenic cultures or co-culture with feeder cells; but no universally accepted standard method is currently available to evaluate anti-Pneumocystis molecules in vitro. Thus, we chose to explore the use of the SYTO-13 dye, as a new indicator of Pneumocystis viability. In the present work, we established the experimental conditions to define the in vitro pharmacodynamic parameters (EC50, Emax) of marketed compounds (trimethoprim/sulfamethoxazole, pentamidine, atovaquone) in order to specifically measure the intrinsic activity of these anti-P. carinii molecules using the SYTO-13 dye for the first time. Co-labelling the fungal organisms with anti-P. carinii specific antibodies enabled the measurement of viability of Pneumocystis organisms while excluding host debris from the analysis. Moreover, contrary to microscopic observation, large numbers of fungal cells can be analyzed by flow cytometry, thus increasing statistical significance and avoiding misreading during fastidious quantitation of stained organisms. In conclusion, the SYTO-13 dye allowed us to show a reproducible dose/effect relationship for the tested anti-Pneumocystis drugs.
Collapse
Affiliation(s)
- Annie Standaert-Vitse
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
| | - Cécile-Marie Aliouat-Denis
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
| | - Anna Martinez
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
- RNA Processing Research Group, Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan
| | - Sara Khalife
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
- Centre AZM pour la Recherche en Biotechnologie et ses Applications, Laboratoire Microbiologie, Santé et Environnement, Université Libanaise, Tripoli, Lebanon
| | - Muriel Pottier
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
| | - Nausicaa Gantois
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
| | - Eduardo Dei-Cas
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
- CHRU Lille, Biology & Pathology Center, Parasitology-Mycology, Lille, France
| | - El Moukhtar Aliouat
- Biology & Diversity of Emerging Eukaryotic Pathogens (BDEEP), Center for Infection and Immunity of Lille (CIIL), INSERM U1019, CNRS UMR 8204, University of Lille, Pasteur Institute of Lille, Lille, France
- * E-mail:
| |
Collapse
|
3
|
Singhal A, Aliouat EM, Hervé M, Mathys V, Kiass M, Creusy C, Delaire B, Tsenova L, Fleurisse L, Bertout J, Camacho L, Foo D, Tay HC, Siew JY, Boukhouchi W, Romano M, Mathema B, Dartois V, Kaplan G, Bifani P. Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS One 2011; 6:e18632. [PMID: 21533270 PMCID: PMC3075263 DOI: 10.1371/journal.pone.0018632] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Accepted: 03/14/2011] [Indexed: 11/29/2022] Open
Abstract
Background Despite the availability of many animal models for tuberculosis (TB) research, there still exists a need for better understanding of the quiescent stage of disease observed in many humans. Here, we explored the use of the Wistar rat model for the study of protective immunity and control of Mycobacterium tuberculosis (Mtb) infection. Methodology/Principal Findings The kinetics of bacillary growth, evaluated by the colony stimulating assay (CFU) and the extent of lung pathology in Mtb infected Wistar rats were dependent on the virulence of the strains and the size of the infecting inoculums. Bacillary growth control was associated with induction of T helper type 1 (Th1) activation, the magnitude of which was also Mtb strain and dose dependent. Histopathology analysis of the infected lungs demonstrated the formation of well organized granulomas comprising epithelioid cells, multinucleated giant cells and foamy macrophages surrounded by large numbers of lymphocytes. The late stage subclinical form of disease was reactivated by immunosuppression leading to increased lung CFU. Conclusion The Wistar rat is a valuable model for better understanding host-pathogen interactions that result in control of Mtb infection and potentially establishment of latent TB. These properties together with the ease of manipulation, relatively low cost and well established use of rats in toxicology and pharmacokinetic analyses make the rat a good animal model for TB drug discovery.
Collapse
Affiliation(s)
- Amit Singhal
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - El Moukhtar Aliouat
- Department of Parasitology-Mycology, Faculty of Biological and Pharmaceutical Sciences, University of Lille-Nord-de-France, Lille, France
- Biology and Diversity of Emergent Eukaryotic Pathogens (BDEEP)–Center for Infection and Immunity of Lille, Pasteur Institute of Lille, Inserm U1019, CNRS UMR 8204, University Lille-Nord-de-France, Lille, France
| | - Maxime Hervé
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - Vanessa Mathys
- Communicable and Infectious Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - Mehdi Kiass
- Communicable and Infectious Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - Colette Creusy
- Groupe Hospitalier de 1'Institut Catholique Lillois (GHICL), Hôpital Saint Vincent, Université Catholique de Lille, Lille, France
| | - Baptiste Delaire
- Groupe Hospitalier de 1'Institut Catholique Lillois (GHICL), Hôpital Saint Vincent, Université Catholique de Lille, Lille, France
| | - Liana Tsenova
- Public Health Research Institute (PHRI), TB Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
| | - Laurence Fleurisse
- Groupe Hospitalier de 1'Institut Catholique Lillois (GHICL), Hôpital Saint Vincent, Université Catholique de Lille, Lille, France
| | | | - Luis Camacho
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - Damian Foo
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - Hui Chien Tay
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - Jie Yee Siew
- Novartis Institute for Tropical Diseases, Singapore, Singapore
| | - Warda Boukhouchi
- Communicable and Infectious Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - Marta Romano
- Communicable and Infectious Diseases, Scientific Institute of Public Health, Brussels, Belgium
| | - Barun Mathema
- Public Health Research Institute (PHRI), TB Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
| | | | - Gilla Kaplan
- Public Health Research Institute (PHRI), TB Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
| | - Pablo Bifani
- Novartis Institute for Tropical Diseases, Singapore, Singapore
- * E-mail:
| |
Collapse
|
4
|
Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2005; 17:770-82, table of contents. [PMID: 15489347 PMCID: PMC523555 DOI: 10.1128/cmr.17.4.770-782.2004] [Citation(s) in RCA: 169] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Pneumocystis infection in humans was originally described in 1942. The organism was initially thought to be a protozoan, but more recent data suggest that it is more closely related to the fungi. Patients with cellular immune deficiencies are at risk for the development of symptomatic Pneumocystis infection. Populations at risk also include patients with hematologic and nonhematologic malignancies, hematopoietic stem cell transplant recipients, solid-organ recipients, and patients receiving immunosuppressive therapies for connective tissue disorders and vasculitides. Trimethoprim-sulfamethoxazole is the agent of choice for prophylaxis against Pneumocystis unless a clear contraindication is identified. Other options include pentamidine, dapsone, dapsone-pyrimethamine, and atovaquone. The risk for PCP varies based on individual immune defects, regional differences, and immunosuppressive regimens. Prophylactic strategies must be linked to an ongoing assessment of the patient's risk for disease.
Collapse
Affiliation(s)
- Martin Rodriguez
- Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St., GRJ 504, Boston, MA 02114, USA
| | | |
Collapse
|